TScan Therapeutics (NASDAQ:TCRX) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research report sent to investors on Wednesday,Benzinga reports. They currently have a $15.00 price target on the stock.

Other analysts also recently issued reports about the company. Wedbush restated an “outperform” rating and issued a $7.00 price target (down from $10.00) on shares of TScan Therapeutics in a research note on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of TScan Therapeutics in a report on Tuesday, November 12th.

TScan Therapeutics Stock Performance

Shares of NASDAQ TCRX opened at $2.85 on Wednesday. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. TScan Therapeutics has a 12 month low of $2.60 and a 12 month high of $9.69. The stock has a 50 day moving average of $4.82 and a 200-day moving average of $5.87. The company has a market capitalization of $152.10 million, a P/E ratio of -2.69 and a beta of 0.79.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.03. The company had revenue of $1.05 million during the quarter, compared to the consensus estimate of $2.86 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. As a group, equities research analysts predict that TScan Therapeutics will post -1.12 EPS for the current year.

Insider Buying and Selling

In other news, Director Barbara Klencke acquired 5,000 shares of TScan Therapeutics stock in a transaction that occurred on Monday, September 23rd. The shares were acquired at an average price of $5.29 per share, for a total transaction of $26,450.00. Following the transaction, the director now directly owns 45,000 shares of the company’s stock, valued at approximately $238,050. The trade was a 12.50 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.76% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On TScan Therapeutics

Institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP bought a new stake in shares of TScan Therapeutics in the 2nd quarter valued at about $70,000. The Manufacturers Life Insurance Company bought a new stake in shares of TScan Therapeutics in the 2nd quarter valued at about $90,000. SG Americas Securities LLC bought a new stake in shares of TScan Therapeutics in the 3rd quarter valued at about $78,000. XTX Topco Ltd bought a new stake in shares of TScan Therapeutics in the 3rd quarter valued at about $112,000. Finally, Cornercap Investment Counsel Inc. bought a new stake in shares of TScan Therapeutics during the 2nd quarter valued at about $134,000. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.